AEON Biopharma Inc.
(AEON)
undefined
undefined%
At close: undefined
0.22
0.83%
Pre-market Jan 08, 2025, 06:15 AM EST
Company Description
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions.
It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis.
The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019.
AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
AEON Biopharma Inc.
| Country | United States |
| IPO Date | Jul 24, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Marc Forth |
Contact Details
Address: 4040 Macarthur Boulevard Newport Beach, California United States | |
| Website | http://www.aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001622667 |
| CUSIP Number | 00775E102 |
| ISIN Number | US00791X1000 |
| Employer ID | 45-4777018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc Forth | Principal Financial Officer, President, Chief Executive Officer & Director |
| Alex Wilson | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Jennifer Sy | Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2022 | D | Filing |
| Aug 11, 2022 | D | Filing |
| Dec 29, 2021 | RW | Filing |
| Oct 07, 2021 | S-1/A | [Amend] Filing |
| Oct 06, 2021 | S-1/A | [Amend] Filing |
| Oct 04, 2021 | S-1/A | [Amend] Filing |
| Sep 17, 2021 | S-1 | Filing |
| Sep 14, 2021 | DRS/A | [Amend] Filing |
| Jul 21, 2021 | DRS/A | [Amend] Filing |
| Jun 08, 2021 | DRS/A | [Amend] Filing |